Clinical Milestones Preceding the Diagnosis of Multiple System Atrophy and Progressive Supranuclear Palsy: A Retrospective Cohort Study.

Advance care planning Delayed diagnosis Multiple System Atrophy Progressive supranuclear palsy

Journal

Journal of movement disorders
ISSN: 2005-940X
Titre abrégé: J Mov Disord
Pays: Korea (South)
ID NLM: 101527867

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 30 01 2019
accepted: 29 04 2019
pubmed: 9 8 2019
medline: 9 8 2019
entrez: 9 8 2019
Statut: ppublish

Résumé

Multiple System Atrophy (MSA) and progressive supranuclear palsy (PSP) are rapidly progressive forms of degenerative Parkinsonism. The difficulties of diagnosing MSA and PSP in their early stages may lead to delayed referral to appropriate specialists and distress to patients, as well as delaying symptomatic treatment and participation in clinical trials. This work aimed to describe the symptoms that patients with MSA and PSP developed and plot their emergence relative to final diagnosis using a median onset in months. Forty-seven patients from the United Kingdom with MSA or PSP diagnosed by a movement disorder specialist were interviewed with carers or relatives to establish milestone onset. This was corroborated using clinical notes and letters. In the MSA cohort (n = 23), autonomic symptoms (median 5.5 months before diagnosis) and falls (median 1 month before diagnosis) were the two clinical milestones which occurred before diagnosis. In the PSP cohort (n = 24), falling was the only milestone which occurred before diagnosis (median of 18.5 months). This Study Shows That Psp Patients Experience Falling More Than A Year And A Half An Average Before Receiving A Diagnosis And Although Msa Patients Also Tended To Fall, This Was Much Closer To The Time Of Diagnosis. Further Work With Larger Cohorts May Illustrate Whether These Preliminary Findings Can Be Generalised To Guide Diagnosis And Management.

Identifiants

pubmed: 31390854
pii: jmd.19015
doi: 10.14802/jmd.19015
pmc: PMC6763719
doi:

Types de publication

Journal Article

Langues

eng

Pagination

177-183

Références

Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
J Neurol. 2014 Aug;261(8):1575-83
pubmed: 24888315
Neurology. 1996 Jul;47(1):1-9
pubmed: 8710059
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
J Mov Disord. 2016 Jan;9(1):3-13
pubmed: 26828211
Brain. 2008 May;131(Pt 5):1362-72
pubmed: 18385183
Brain. 2005 Jun;128(Pt 6):1247-58
pubmed: 15788542
Res Nurs Health. 2008 Apr;31(2):180-91
pubmed: 18183564
J Parkinsons Dis. 2012;2(1):7-18
pubmed: 23939403
Brain. 2015 Dec;138(Pt 12):3623-31
pubmed: 26369944
J Neurol Neurosurg Psychiatry. 2017 May;88(5):402-411
pubmed: 28250027
Postgrad Med J. 2016 Jul;92(1089):412-7
pubmed: 27129911
J Neurol Neurosurg Psychiatry. 2002 Mar;72 Suppl 1:I10-I16
pubmed: 11870198
Parkinsonism Relat Disord. 2013 Nov;19(11):980-5
pubmed: 23968651

Auteurs

Louise Wiblin (L)

Department of Neurosciences, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK.

Rory Durcan (R)

Institute of Neuroscience, Newcastle University, Newcastle-upon-Tyne, UK.

Brook Galna (B)

Institute of Neuroscience, Newcastle University, Newcastle-upon-Tyne, UK.

Mark Lee (M)

St. Benedict's Hospice, Sunderland, UK.

David Burn (D)

Institute of Neuroscience, Newcastle University, Newcastle-upon-Tyne, UK.

Classifications MeSH